Change of 20.77% for Bio-path Holdings Inc (NASDAQ:BPTH)’s shares shorted was recorded. It was issued in April by FINRA the 82,000 shares shorted on BPTH. The up change of 20.77% from 67,900 shares was reported. Previous BPTH’s position will need 1 days to recover. It has 179,700 average volume. Bio-path Holdings Inc’s shares shorted float is 15.57%.

Ticker’s shares touched $18.42 during the last trading session after 0.65% change.Bio-Path Holdings, Inc. has volume of 78,923 shares. Since April 5, 2018 BPTH has declined 83.63% and is downtrending. BPTH underperformed by 88.00% the S&P500.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States.The firm is valued at $46.18 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction.Currently it has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

For more Bio-Path Holdings, Inc. (NASDAQ:BPTH) news released briefly go to: Benzinga.com, Benzinga.com, Benzinga.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “41 Stocks Moving In Monday’s Mid-Day Session – Benzinga” released on March 25, 2019, “30 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on March 22, 2019, “60 Biggest Movers From Friday – Benzinga” with a publish date: March 25, 2019, “58 Biggest Movers From Yesterday – Benzinga” and the last “CLMT, RENN among premarket gainers – Seeking Alpha” with publication date: March 07, 2019.